Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016 (2016), Article ID 6145810, 11 pages
http://dx.doi.org/10.1155/2016/6145810
Review Article

Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis

1Department of Immunology and Biotechnology, University of Pécs, Szigeti ut 12, Pécs 7624, Hungary
2Section of Molecular Medicine, Rush University Medical Center, 1735 West Harrison Street, Chicago, IL 60612, USA

Received 25 September 2015; Accepted 3 January 2016

Academic Editor: Julio Galvez

Copyright © 2016 Reka Kugyelka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. L. Scott, F. Wolfe, and T. W. J. Huizinga, “Rheumatoid arthritis,” The Lancet, vol. 376, no. 9746, pp. 1094–1108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. J. Landré-Beauvais, “The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800,” Joint Bone Spine, vol. 68, no. 2, pp. 130–143, 2001. View at Google Scholar
  3. G. Azizi, F. Jadidi-Niaragh, and A. Mirshafiey, “Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis,” International Journal of Rheumatic Diseases, vol. 16, no. 3, pp. 243–253, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Schiff, “Abatacept treatment for rheumatoid arthritis,” Rheumatology, vol. 50, no. 3, pp. 437–449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. S. P. Singh, H. H. Zhang, J. F. Foley, M. N. Hedrick, and J. M. Farber, “Human T cells that are able to produce IL-17 express the chemokine receptor CCR6,” Journal of Immunology, vol. 180, no. 1, pp. 214–221, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. E. V. Acosta-Rodriguez, G. Napolitani, A. Lanzavecchia, and F. Sallusto, “Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells,” Nature Immunology, vol. 8, no. 9, pp. 942–949, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Segura, M. Touzot, A. Bohineust et al., “Human inflammatory dendritic cells induce Th17 cell differentiation,” Immunity, vol. 38, no. 2, pp. 336–348, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J. P. van Hamburg, P. S. Asmawidjaja, N. Davelaar et al., “Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production,” Arthritis & Rheumatism, vol. 63, no. 1, pp. 73–83, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. S. M. J. Paulissen, J. P. van Hamburg, W. Dankers, and E. Lubberts, “The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis,” Cytokine, vol. 74, no. 1, pp. 43–53, 2015. View at Publisher · View at Google Scholar
  10. L. G. M. van Baarsen, M. C. Lebre, D. van der Coelen et al., “Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?” Arthritis Research & Therapy, vol. 16, no. 4, article 426, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Zizzo, M. De Santis, S. L. Bosello et al., “Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis,” Clinical Immunology, vol. 138, no. 1, pp. 107–116, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Kondo, Z. Yao, M. Tahara et al., “Involvement of RORγt-overexpressing T cells in the development of autoimmune arthritis in mice,” Arthritis Research & Therapy, vol. 17, no. 1, 2015. View at Publisher · View at Google Scholar
  13. K. Hirota, H. Yoshitomi, M. Hashimoto et al., “Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model,” Journal of Experimental Medicine, vol. 204, no. 12, pp. 2803–2812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Rouvier, M.-F. Luciani, M.-G. Mattei, F. Denizot, and P. Golstein, “CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus Saimiri gene,” The Journal of Immunology, vol. 150, no. 12, pp. 5445–5456, 1993. View at Google Scholar · View at Scopus
  15. Z. Yao, W. C. Fanslow, M. F. Seldin et al., “Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor,” Immunity, vol. 3, no. 6, pp. 811–821, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Fossiez, O. Djossou, P. Chomarat et al., “T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines,” Journal of Experimental Medicine, vol. 183, no. 6, pp. 2593–2603, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Kennedy, D. L. Rossi, S. M. Zurawski et al., “Mouse IL-17: a cytokine preferentially expressed by αβTCR+CD4−CD8−T cells,” Journal of Interferon & Cytokine Research, vol. 16, no. 8, pp. 611–617, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. T. R. Mosmann, H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman, “Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins,” The Journal of Immunology, vol. 136, no. 7, pp. 2348–2357, 1986. View at Google Scholar
  19. L. H. Glimcher and K. M. Murphy, “Lineage commitment in the immune system: the T helper lymphocyte grows up,” Genes and Development, vol. 14, no. 14, pp. 1693–1711, 2000. View at Google Scholar · View at Scopus
  20. L. Steinman, “A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage,” Nature Medicine, vol. 13, no. 2, pp. 139–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Infante-Duarte, H. F. Horton, M. C. Byrne, and T. Kamradt, “Microbial lipopeptides induce the production of IL-17 in Th cells,” Journal of Immunology, vol. 165, no. 11, pp. 6107–6115, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. S. L. Gaffen, J. M. Kramer, J. J. Yu, and F. Shen, “The IL-17 cytokine family,” Vitamins and Hormones, vol. 74, pp. 255–282, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Gu, L. Wu, and X. Li, “IL-17 family: cytokines, receptors and signaling,” Cytokine, vol. 64, no. 2, pp. 477–485, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Ouyang, J. K. Kolls, and Y. Zheng, “The biological functions of T helper 17 cell effector cytokines in inflammation,” Immunity, vol. 28, no. 4, pp. 454–467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Chabaud, J. M. Durand, N. Buchs et al., “Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium,” Arthritis and Rheumatism, vol. 42, no. 5, pp. 963–970, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Florencio-Silva, G. R. da Sasso, E. Sasso-Cerri, M. J. Simões, and P. S. Cerri, “Biology of bone tissue: structure, function, and factors that influence bone cells,” BioMed Research International, vol. 2015, Article ID 421746, 17 pages, 2015. View at Publisher · View at Google Scholar
  27. S. M. Jung, K. W. Kim, C.-W. Yang, S.-H. Park, and J. H. Ju, “Cytokine-mediated bone destruction in rheumatoid arthritis,” Journal of Immunology Research, vol. 2014, Article ID 263625, 15 pages, 2014. View at Publisher · View at Google Scholar
  28. T. Dimitroulas, S. N. Nikas, P. Trontzas, and G. D. Kitas, “Biologic therapies and systemic bone loss in rheumatoid arthritis,” Autoimmunity Reviews, vol. 12, no. 10, pp. 958–966, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. K.-W. Kim, H.-R. Kim, B.-M. Kim, M.-L. Cho, and S.-H. Lee, “Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis,” The American Journal of Pathology, vol. 185, no. 11, pp. 3011–3024, 2015. View at Publisher · View at Google Scholar
  30. S. Kotake, N. Udagawa, N. Takahashi et al., “IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis,” The Journal of Clinical Investigation, vol. 103, no. 9, pp. 1345–1352, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Chabaud, E. Lubberts, L. Joosten, W. van Den Berg, and P. Miossec, “IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis,” Arthritis Research, vol. 3, no. 3, pp. 168–177, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. I. E. Adamopoulos, C.-C. Chao, R. Geissler et al., “Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors,” Arthritis Research and Therapy, vol. 12, no. 1, article R29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Caccamo, C. La Mendola, V. Orlando et al., “Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells,” Blood, vol. 118, no. 1, pp. 129–138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. E. C. Keystone, C. Rittershaus, N. Wood et al., “Elevation of a gamma delta T cell subset in peripheral blood and synovial fluid of patients with rheumatoid arthritis,” Clinical and Experimental Immunology, vol. 84, no. 1, pp. 78–82, 1991. View at Google Scholar · View at Scopus
  35. Y. Ito, T. Usui, S. Kobayashi et al., “Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 60, no. 8, pp. 2294–2303, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Pappalardo and K. Thompson, “Activated γδ T cells inhibit osteoclast differentiation and resorptive activity in vitro,” Clinical and Experimental Immunology, vol. 174, no. 2, pp. 281–291, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Pöllinger, T. Junt, B. Metzler et al., “Th17 cells, not IL-17+γδ T cells, drive arthritic bone destruction in mice and humans,” The Journal of Immunology, vol. 186, no. 4, pp. 2602–2612, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Hirota, M. Hashimoto, H. Yoshitomi et al., “T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis,” Journal of Experimental Medicine, vol. 204, no. 1, pp. 41–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Duarte, A. Agua-Doce, V. G. Oliveira, J. E. Fonseca, and L. Grac, “Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice,” PLoS ONE, vol. 5, no. 5, Article ID e10558, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Shiomi, T. Usui, Y. Ishikawa, M. Shimizu, K. Murakami, and T. Mimori, “GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice,” Journal of Immunology, vol. 193, no. 2, pp. 849–859, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. H.-J. Wu, I. I. Ivanov, J. Darce et al., “Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells,” Immunity, vol. 32, no. 6, pp. 815–827, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Katayama, K. Ohmura, N. Yukawa et al., “Neutrophils are essential as a source of IL-17 in the effector phase of arthritis,” PLoS ONE, vol. 8, no. 5, Article ID e62231, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. C. D. Sadik, N. D. Kim, E. Alekseeva, and A. D. Luster, “Il-17RA signaling amplifies antibody-induced arthritis,” PLoS ONE, vol. 6, no. 10, Article ID e26342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. S. R. Pickens, M. V. Volin, A. M. Mandelin II, J. K. Kolls, R. M. Pope, and S. Shahrara, “IL-17 contributes to angiogenesis in rheumatoid arthritis,” Journal of Immunology, vol. 184, no. 6, pp. 3233–3241, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Nakae, S. Saijo, R. Horai, K. Sudo, S. Mori, and Y. Iwakura, “IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5986–5990, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. M.-J. Park, H.-S. Park, H.-J. Oh et al., “IL-17-deficient allogeneic bone marrow transplantation prevents the induction of collagen-induced arthritis in DBA/1J mice,” Experimental and Molecular Medicine, vol. 44, no. 11, pp. 694–705, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Lubberts, M. I. Koenders, B. Oppers-Walgreen et al., “Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion,” Arthritis and Rheumatism, vol. 50, no. 2, pp. 650–659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Qi, F. Kan, X. Ye et al., “A bispecific antibody against IL-1β and IL-17A is beneficial for experimental rheumatoid arthritis,” International Immunopharmacology, vol. 14, no. 4, pp. 770–778, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Zhang, G. Ren, M. Guo et al., “Synergistic effects of interleukin-1β and interleukin-17A antibodies on collagen-induced arthritis mouse model,” International Immunopharmacology, vol. 15, no. 2, pp. 199–205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. Q. Li, G. Ren, L. Xu et al., “Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model,” International Immunopharmacology, vol. 21, no. 1, pp. 119–127, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. A. E. M. van Nieuwenhuijze, F. A. van de Loo, B. Walgreen et al., “Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis,” Arthritis Research & Therapy, vol. 17, article 163, no. 1, 2015. View at Publisher · View at Google Scholar
  52. Y. Yamaguchi, K. Fujio, H. Shoda et al., “IL-17B and IL-17C are associated with TNF-α production and contribute to the exacerbation of inflammatory arthritis,” The Journal of Immunology, vol. 179, no. 10, pp. 7128–7136, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. C. L. Roark, Y. Huang, N. Jin et al., “A canonical Vγ4Vδ4+ γδ T cell population with distinct stimulation requirements which promotes the Th17 response,” Immunologic Research, vol. 55, no. 1–3, pp. 217–230, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Ogura, M. Murakami, Y. Okuyama et al., “Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction,” Immunity, vol. 29, no. 4, pp. 628–636, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Fujimoto, S. Serada, M. Mihara et al., “Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses,” Arthritis and Rheumatism, vol. 58, no. 12, pp. 3710–3719, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Sato, A. Suematsu, K. Okamoto et al., “Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction,” The Journal of Experimental Medicine, vol. 203, no. 12, pp. 2673–2682, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Lubberts, L. A. B. Joosten, M. Chabaud et al., “IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion,” Journal of Clinical Investigation, vol. 105, no. 12, pp. 1697–1710, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. C. A. Murphy, C. L. Langrish, Y. Chen et al., “Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation,” Journal of Experimental Medicine, vol. 198, no. 12, pp. 1951–1957, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. S. R. Pickens, N. D. Chamberlain, M. V. Volin et al., “Local expression of interleukin-27 ameliorates collagen-induced arthritis,” Arthritis and Rheumatism, vol. 63, no. 8, pp. 2289–2298, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Ye, B. Jiang, J. Deng et al., “IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation,” The Journal of Immunology, vol. 194, no. 11, pp. 5110–5119, 2015. View at Publisher · View at Google Scholar
  61. C. K. C. Lo, Q. L. K. Lam, L. Sun et al., “Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production,” Arthritis and Rheumatism, vol. 58, no. 9, pp. 2700–2711, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. N. A. Carter, E. C. Rosser, and C. Mauri, “Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis,” Arthritis Research and Therapy, vol. 14, no. 1, article R32, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Tao, M. Kamanaka, J. Hao et al., “IL-10 signaling in CD4+ T cells is critical for the pathogenesis of collagen-induced arthritis,” Arthritis Research and Therapy, vol. 13, no. 6, article R212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. R. A. Ratsimandresy, E. Duvallet, E. Assier et al., “Active immunization against IL-23p19 improves experimental arthritis,” Vaccine, vol. 29, no. 50, pp. 9329–9336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Vermeire, H. Heremans, M. Vandeputte, S. Huang, A. Billiau, and P. Matthys, “Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice,” The Journal of Immunology, vol. 158, no. 11, pp. 5507–5513, 1997. View at Google Scholar · View at Scopus
  66. H. Kelchtermans, E. Schurgers, L. Geboes et al., “Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-γ and counteraction by interferon-γ,” Arthritis Research and Therapy, vol. 11, no. 4, article R122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Finnegan, M. J. Grusby, C. D. Kaplan et al., “IL-4 and IL-12 regulate proteoglycan-induced arthritis through stat-dependent mechanisms,” Journal of Immunology, vol. 169, no. 6, pp. 3345–3352, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. P. D. Doodes, Y. Cao, K. M. Hamel et al., “Development of proteoglycan-induced arthritis is independent of IL-17,” The Journal of Immunology, vol. 181, no. 1, pp. 329–337, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. P. D. Doodes, Y. Cao, K. M. Hamel et al., “IFN-γ regulates the requirement for IL-17 in proteoglycan-induced arthritis,” Journal of Immunology, vol. 184, no. 3, pp. 1552–1559, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. W. Hueber, D. D. Patel, T. Dryja et al., “Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis,” Science Translational Medicine, vol. 2, no. 52, Article ID 52ra72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. M. C. Genovese, P. Durez, H. B. Richards et al., “Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study,” Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 863–869, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. M. C. Genovese, P. Durez, H. B. Richards et al., “One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study,” Journal of Rheumatology, vol. 41, no. 3, pp. 414–421, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. M. C. Genovese, F. Van den Bosch, S. A. Roberson et al., “LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study,” Arthritis and Rheumatism, vol. 62, no. 4, pp. 929–939, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. M. C. Genovese, M. Greenwald, C.-S. Cho et al., “A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors,” Arthritis & Rheumatology, vol. 66, no. 7, pp. 1693–1704, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. D. A. Martin, M. Churchill, L. F. Flores-Suarez et al., “A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis,” Arthritis Research and Therapy, vol. 15, no. 5, article R164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. K. Pavelka, Y. Chon, R. Newmark, S.-L. Lin, S. Baumgartner, and N. Erondu, “A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate,” The Journal of Rheumatology, vol. 42, no. 6, pp. 912–919, 2015. View at Publisher · View at Google Scholar
  77. N. Sakaguchi, T. Takahashi, H. Hata et al., “Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice,” Nature, vol. 426, no. 6965, pp. 454–460, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. V. Kouskoff, A.-S. Korganow, V. Duchatelle, C. Degott, C. Benoist, and D. Mathis, “Organ-specific disease provoked by systemic autoimmunity,” Cell, vol. 87, no. 5, pp. 811–822, 1996. View at Publisher · View at Google Scholar · View at Scopus
  79. I. I. Ivanov, R. D. L. Frutos, N. Manel et al., “Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine,” Cell Host and Microbe, vol. 4, no. 4, pp. 337–349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Nakae, A. Nambu, K. Sudo, and Y. Iwakura, “Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice,” Journal of Immunology, vol. 171, no. 11, pp. 6173–6177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Sarkar, L. A. Tesmer, V. Hindnavis, J. L. Endres, and D. A. Fox, “Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4,” Arthritis and Rheumatism, vol. 56, no. 1, pp. 89–100, 2007. View at Publisher · View at Google Scholar · View at Scopus
  82. F. Boldizsar, O. Tarjanyi, P. Nemeth, K. Mikecz, and T. T. Glant, “Th1/Th17 polarization and acquisition of an arthritogenic phenotype in arthritis-susceptible BALB/c, but not in MHC-matched, arthritis-resistant DBA/2 mice,” International Immunology, vol. 21, no. 5, pp. 511–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. T. T. Glant, K. Mikecz, A. Arzoumanian, and A. R. Poole, “Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology,” Arthritis and Rheumatism, vol. 30, no. 2, pp. 201–212, 1987. View at Publisher · View at Google Scholar · View at Scopus
  84. T. T. Glant, A. Finnegan, and K. Mikecz, “Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics,” Critical Reviews in Immunology, vol. 23, no. 3, pp. 199–250, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Finnegan, K. Mikecz, P. Tao, and T. T. Glant, “Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines,” The Journal of Immunology, vol. 163, no. 10, pp. 5383–5390, 1999. View at Google Scholar · View at Scopus
  86. K. Papp, C. Leonardi, A. Menter et al., “Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment,” Journal of the American Academy of Dermatology, vol. 71, no. 6, pp. 1183–1190.e3, 2014. View at Publisher · View at Google Scholar
  87. P. Miossec and J. K. Kolls, “Targeting IL-17 and TH17 cells in chronic inflammation,” Nature Reviews Drug Discovery, vol. 11, no. 10, pp. 763–776, 2012. View at Publisher · View at Google Scholar
  88. I. B. McInnes, J. Sieper, J. Braun et al., “Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase ii proof-of-concept trial,” Annals of the Rheumatic Diseases, vol. 73, no. 2, pp. 349–356, 2014. View at Publisher · View at Google Scholar · View at Scopus